U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Rivaroxaban (Xarelto): Treatment of Venous Thromboembolic Events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and Prevention of Recurrent DVT and PE [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug.

Cover of Rivaroxaban (Xarelto)

Rivaroxaban (Xarelto): Treatment of Venous Thromboembolic Events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and Prevention of Recurrent DVT and PE [Internet].

Show details

SUMMARY

Rivaroxaban (Xarelto) is available as 15 mg and 20 mg tablets. The manufacturer priced rivaroxaban at $2.84 per tablet regardless of strength (flat pricing), or at $5.68 daily (days 1 to 21) and $2.84 daily (day 22 onward). The manufacturer assumed equal efficacy and harms compared with low-molecular-weight heparins plus a vitamin K antagonist (based on the EINSTEIN PE trial), and submitted a cost-minimization analysis. It considered treatment regimens used in the EINSTEIN PE trial and treatment durations of three, six, and 12 months. The manufacturer concluded that rivaroxaban is cost saving at three and six months, with results driven by the lower monitoring costs for rivaroxaban. However, given that the cost of rivaroxaban is significantly greater than that of vitamin K antagonist, for longer treatment duration of ≥ 12 months (indicated for a considerable proportion of patients), rivaroxaban is more costly.

Copyright © CADTH 2015.

You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK344332
Contents

Views

  • PubReader
  • Print View
  • Cite this Page

Other titles in this collection

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...